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Association of Obstetrics and Gynecology and Hsu Chien-Tien Cancer
FoundationThe Hsu Chien-Tien Cancer Foundation, established in 1975,
has supported and encouraged cancer research for a long time.
In this issue of the Taiwanese Journal of Obstetrics and Gynecology,
we are happy to introduce the winners of the 2015 Hsu Chien-Tien
Cancer Foundation Outstanding Research Paper Award. The
awards were selected from among female cancer research papers
published in 2015, and the ﬁrst author should be a member of the
Taiwan Association of Obstetrics and Gynecology (TAOG). The
golden award goes to Dr Ying-Cheng Chiang, for his research pa-
per entitled “Overexpression of CHI3L1 is associationwith chemo-
resistance and poor outcome of epithelial ovarian carcinoma” [1].
Dr Wen-Fang Cheng, the corresponding author of this paper, is a
professor at the National Taiwan University Hospital. The silver
award winner is Dr Chia-Yen Huang, for his research paper enti-
tled “Urokinase-type plasminogen activator resulting from endo-
metrial carcinogenesis enhances tumor invasion and correlates
with poor outcome of endometrial carcinoma patients” [2]. The
corresponding author of this article is also Dr Wen-Fang Cheng.
Dr Cheng is the biggest winner at the Annual Meeting of the
Taiwan Association of Obstetrics and Gynecology, because his
two students obtained the ﬁrst and second awards of the 2015
Hsu Chien-Tien Cancer Foundation Outstanding Research Paper
Award in this year. The copper award winner is Dr Keng-Fu Hsu,
for his research paper entitled “Overexpression of the RNA-
binding proteins Lin28B and IGF2BP3 (IMP3) is associated with
chemoresistance and poor disease outcome in ovarian cancer”
[3]. All winners received their awards at the Annual Meeting of
the Taiwan Association of Obstetrics and Gynecology on March 5
and 6, 2016, held in Taipei, Taiwan.
Of these three papers, two articles focused on chemoresistance
and worse outcomes in ovarian cancers, and the other focused on
tumor invasion and worse outcome in endometrial cancer (EC).
Epithelial ovarian cancer (EOC) and EC have become two of the
most important gynecological cancers in Taiwan [4,5]. The charac-
teristic of tumor behavior, including chemoresistance, is a key fac-
tor for failure during cancer treatment. Therefore, there are
thousands of papers available on this topic. Dr Chiang found
that CHI3L1 (chitinase 3-like 1, and its product, YKL-40) could
be a prognostic biomarker for EOC, because the overexpression
of CHI3L1 was associated with high-grade cell type, such as serous
histological type, advanced stage, and chemoresistance. In addi-
tion, patients with high CHI3L1 expression had a high risk of
recurrence and death, contributing to a shorter progression-freehttp://dx.doi.org/10.1016/j.tjog.2016.05.008
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).survival (PFS) and overall survival (OS) [1]. The possible mecha-
nism of CHI3L1 for chemoresistance might be mediated through
upregulating Mcl-1 (myeloid cell leukemia-1) [1]. Dr Hsu found
that EOC patients with elevated expression of the human high-
afﬁnity copper transporter 1 (hCTR1) and low expression of
insulin-like growth factor (IGF) 2 messenger ribonucleic acid
(mRNA)-binding protein 3 (IMP3) and lin28B had better PFS [3].
In the same year, Dr Cheng published an interesting article enti-
tled “Insulin-like growth factors inhibit dendritic cell-mediated
antitumor immunity through regulating extracellular signal-
regulated kinase (ERK)1/2 phosphorylation and p38 dephosphor-
ylation” and found that patients with advanced-stage EOC had
higher IGF-1 and IGF-2 concentrations in their ascites compared
with patients with early-stage EOC, and these increased IGFs
would suppress dendritic cell’s maturation, and the underlying
mechanism might be mediated through the dephosphorylation
of ERK1/2, protein kinase B (Akt), and p38 mitogen-activated pro-
tein kinase (p38MAPK) molecules [6]. Dr Huang reported that
urokinase-type plasminogen activator (uPA) was the only inde-
pendent poor prognostic factor for disease-free survival in pa-
tients with endometrial endometrioid carcinoma, and the
underlying mechanism of uPA enhancing tumor migration, inva-
sive capabilities of endometrial tumor cells, might be mediated
through the phosphorylation of ERK1/2, Akt, and p38MAPK mol-
ecules [3].
Besides the above-mentioned papers [1e3], last year there were
also many excellent works for female cancer research. For example,
Dr Yi-HuiWu, supervised by Professor Cheng-Yang Chou, published
an excellent article entitled “COL11A1 confers chemoresistance on
ovarian cancer cells through the activation of Akt/c/EBPb pathway
and PDK1 stabilization,” and the authors found that collagen type
XI alpha 1 (COL11A1) is a chemotherapy response-associated
gene, and EOC patients with high COL11A1 mRNA levels are signif-
icantly associated with poor chemoresponse and worse outcome
[7]. In fact, Dr Chou is currently involved in evenmore research pro-
jects in gynecological cancers [3,7,8].
Other research works in Taiwan are also impressive. For
example, Professor Eing-Mei Tsai (Kaohsiung Medical University
Hospital) found that breast cancer patients with lower serum levels
of microRNA-125a-5p had higher tumor grade, more lymph node
metastases, and larger tumor size, and ﬁnally a shorter survival
compared with long-term survivors [9]. Dr Chi-Mu Chuang (Taipei
Veterans General Hospital) modiﬁed the drug-transport system toy Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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demonstrated better tumor endocytosis and time-dependent
gradual increase of intracellular drug uptake than nontargeting
liposomal nanoparticles [10]. Professor Angel Chao (Chang Gung
Memorial Hospital) found that brain-speciﬁc angiogenesis inhibitor
1 (BAI1)-associated protein 2-like 1 (BAIAP2L1), also known as in-
sulin receptor tyrosine kinase substrate (IRTKS), contributed to
the intraperitoneal metastases of EOC patients, because BAIAP2L1
protein expression in metastatic lesions was higher than the corre-
sponding primary tumors [11]. Professor Po-HuiWang (Chung Shan
Medical University) found that patients with cervical cancer with
positive voltage-dependent anion channel 1 (VDAC1) immunoreac-
tivity exhibited deep stromal invasion (>10 mm in depth) and large
tumor size (>4 cm in diameter), contributing to higher recurrence
and poorer OS than those with negative VDAC1 [12]. Professor
Hung-Cheng Lai (Taipei Medical University and National Defense
Medical Center) modiﬁed the original niclosamide (poor water sol-
ubility) to nano-niclosamide (nano-NI), which showed rapid ab-
sorption (reaching the maximum plasma concentration within 5
minutes) and improved the bioavailability (the estimated bioavail-
ability for oral nano-NI was 25%) [13]. Dr Chih-Long Chang (Mackay
Medical College and Mackay Memorial Hospital) used pegylated
silica-core gold nanoshells in vivowith external near-infrared laser
irradiation to provide a tool for future intraperitoneal hyperthermia
therapy [14]. Professor Tang-Yuan Chu (Tzu Chi University and
Buddhist Tzu Chi General Hospital) tried to explore the possible
mechanism of malignant transformation of the fallopian tube
ﬁmbriae, and their study revealed that reactive oxygen species
and mitogens in mature ovarian follicles could initiate the transfor-
mation of ﬁmbria epithelium in the context of p53 loss, and mela-
tonin is a potent preventive agent [15]. Dr Sheng-Mou Hsiao (Far
Eastern Memorial Hospital) studied the relationship between his-
tone H3 lysine 9 (H3K9) methylation and myometrial invasion of
EC and found that G9a (H3K9 methyltransferase) might involve
the myometrial invasion of EC, and the underlying mechanism
might be mediated by repression of E-cadherin [16]. As editors,
we also provide a platform (Taiwanese Journal of Obstetrics and Gy-
necology) to publish excellent research works for female cancers
[17e20]. Finally, we regret that many outstanding research studies
could not be mentioned in this brief report; still, the efforts of these
researchers to improve the global health of women, especially fe-
male cancers, should be applauded.
Lastly, we are pleased to congratulate all three highly accom-
plished doctors for having won the 2015 Hsu Chien-Tien Cancer
Foundation Outstanding Research Paper Award, and we offer our
great respect and admiration for our colleagues in Taiwan and
thank them for their great contribution in promoting women’s
health, especially in the ﬁeld of female cancer research.Conﬂicts of interest
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